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Abstract 
 
Doxorubicin is one of chemotherapeutic agent used for cancer therapy. However, 
doxorubicin usage causes some adverse effects, such as lymphocyte, CD4+ and CD8+ cells 
number. Therefore, the co-chemotherapeutic agent is required to reduce the 
imunosuppression effect. Cardamom (Elettaria cardamomum) contains terpenoid 1,8 cineol. 
This research aimed to know the effect of Elettaria cardamomum distillate (ECD) in 
combination with doxorubicin on Sprague Dawley rat’s hematology profile and the amount of 
CD4+ and CD8+ cells. The experiment was done for 13 days using 6 groups of rats: I 
doxorubicin (dox) 15 mg/kg BW; II dox + ECD5 mg/kg BW; III dox + ECD 50 mg/kg BW; IV 
dox + ECD 100 mg/kg BW; V ECD 100 mg/kg BW; VI control without treatment. The 
hematology profile and the amount of CD4+ and CD8+ were counted before and after 
treatment using flowcytometer. The results show that ECD increases the amount of 
lymphocyte, white blood, CD4+ and CD8+ cells in dose dependent manner in doxorubicin 
treated rats. Based on the data, it can be concluded that ECD is potential to be developed as 
immunostimulant agent for chemotherapy.  
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INTRODUCTION 
 
Chemotherapy is the treatment method 
using chemical drugs, remains a first line in the 
treatment of cancer until now. Doxorubicin, 
anthracycline antibiotics class has activity 
against various types of cancer cells and drug of 
choice in cancer therapy. However, the use of 
doxorubicin is reported to have side effects 
included hair loss, sore throat, even 
cardiotoxicity (Bustova, 2009). In addition, 
doxorubicin also affects the immune system by 
decreasing the production of interferon-γ, 
natural killer cells (NK), the expression of IL-2, 
proliferation of lymphocytes, and the ratio of 
CD4 + / CD8 + (Zhang et al., 2005). Therefore, 
co-chemotherapeutic agent works 
synergistically with doxorubicin is needed to 
counteract the effects of immunosuppression of 
doxorubicin. 
Co-chemotherapeutic agents coming 
from natural ingredients which can affect the 
immune system is a prospective. One of the 
potential plants is cardamom (Elettaria 
cardamomum). Cardamom contains 
monoterpenes 1,8-cineol which acts as a 
chemo-preventive and chemotherapy at the 
same time (Wattenberg and Morse, 1992) and 
potential as an agent inducer of apoptosis in 
cancer cells (Huang et al, 1999). In addition, 
1,8-cineol also werereported to stimulate 
immune response through increased phagocytic 
ability of macrophages (Serafino et al, 2008). 
However, research on the development 
of Elletaria cardamomum distillate (ECD) is 
still lacking, previous research is still limited to 
in vitro studies. In fact not much research to 
develop the potential of the compound 1,8-
cineol from ECD as an immunomodulatory 
agent. Therefore, research is needed on ECD 
immunomodulatory activities in vivo, 
particularly as co-chemotherapeutic agent of 
doxorubicin. This study evaluates effect of 
cardamomum on immune system based on 
lymphocyte, CD4+, and CD8+ number in vivo. 
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MATERIALS AND METHODS 
 
Plant Collection and Identification  
Cardamomum (Elleteria cardamomum) 
was obtained from Kapulogo village, 
Wonosobo, Central Java and was identified at 
Biology of Pharmacy, Faculty of Pharmacy, 
Universitas Gadjah Mada. Cardamomum 
powder was extracted by distillation method for 
5 days with aquadest (E.Merck, Darmstadt, 
Germany). Distillate was collected and Na2SO4 
was added to remove water spots, then filtered 
and separated. 
 
1,8-cineol Identification using Gas 
Chromatography 
One mL ECD obtained was injected into 
the GC injector using a DB-5MS capillary 
column (dimensions 30 m x 32 mm), flow rate 
1 mL/min, split injection, helium carrier gas 
pressure of 80 kPa, injector temperature 250
o
C, 
interface temperature 280 ° C, temperature 
program 60
o
C to 300
o
C 5 minutes on hold 2 
min (rate of rise of 10 ° C / min), with cineol as 
standard compound. Running of GC carried out 
in the Laboratorium Penelitian dan Pengujian 
Terpadu (LPPT) Universitas Gadjah Mada. 
 
Animals 
A total of 30 female Sprague Dawley 
rats (60days old), weighed from 86 to 112 g 
were purchased from Unit Pengembangan 
Hewan Percobaan Universitas Gadjah Mada. 
The animals were kept for at least one week 
before use, and the rats were given standard 
pellet diet and water ad libitum, and kept on a 
12:12 h light/dark cycle. 
 
Experimental Procedure 
Rats were adapted in cages for one week 
prior to the experiment was treated. Body 
weight of rats were weighed every day during 
the experiment to evaluate the condition of the 
rats, because the rats were stressed or affected 
by drug side effects may decrease appetite so 
the weight will be reduced. An effective dose of 
doxorubicin in this study was 7.5 mg/kg has 
been conducted from orientation that can 
suppress the immune system of rats but did not 
caused mortality.  
Animal tests are grouped into 6 groups, 
namely doxorubicin treatment group (dox), dox 
treatment group + ECD dose I, the treatment 
group dox + ECD dose II, the treatment group 
dox + ECD dose III, the ECD control group, 
and the group without treatment. The number of 
each rat in each group was 6 rats. 
a. Group I, the treatment group was given 
doxorubicin solution at a dose of 7.5 
mg/kgBW intraperitoneal on first and sixth 
day.  
b. Group II, given doxorubicin at a dose of 
7.5 mg/kg BW intraperitoneal on first and 
sixth day, and ECD dose of 5 mg/kg BW in 
1% CMC-Na solvent were oral every day 
fromfirst until eleventh day. 
c. Group III, given doxorubicin at a dose of 
7.5 mg/kg BW intraperitoneal on first and 
sixth day, and ECD dose of 50 mg/kg BW 
in 1% CMC-Na solvent oral every day 
from first until eleventh day. 
d. Group II, given doxorubicin at a dose of 
7.5 mg/kg BW intraperitoneal on first and 
sixth day, and ECD dose of 100 mg/kg BW 
in 1% CMC-Na solvent oral every day 
from first until eleventh day. 
e. Group V, as the ECD control group, ECD 
given at a dose of 100 mg/kg BW in 1% 
CMC-Na oral every day from first until 
eleventh day. 
f. Group VI, as a group without treatment. 
Each rat blood sampled on days 0 and 12 
through ocular vein, then hematology profile 
was analyze with hematology analyzer and 
CD4+ and CD8+ numbers were measured by 
using flowcytometry. 
 
Determination of Total Blood Cells 
Profile with Hematology Analyzer 
Blood samples were taken from test 
animals and stored in EDTA vacutainer. 
Furthermore, the number of leukocytes, 
lymphocytes, neutrophils, and platelets were 
determined by hematology analyzer. Testing is 
done with a hematology analyzer at 
Laboratorium Penelitian dan Pengujian Terpadu 
(LPPT) Universitas Gadjah Mada. 
 
Determination of Total Lymphocyte 
CD4+ and CD8+ by Flowcytometry 
Determination of CD4+ and CD8+ count 
by flowcytometry began by taking blood 
samples from test animals 3 ml and stored in 
EDTA Vacutainer. Whole blood sample were 
prepared and added with reagents. The sample 
was then read by flowcytometer and analyzed 
using the MultiSet program with the observed 
of 15,000cells population. The data were 
generated in the form of CD4 + or CD8 + 
count. Testing was done by flowcytometry at 
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Biomedical Laboratory of the Faculty of 
Medicine, Universitas Sebelas Maret Surakarta. 
 
Data Analysis 
The data generated in the form of the 
number of leukocytes, lymphocytes, 
neutrophils, and platelets, and lymphocytes 
CD4+ and CD8+ in the sample. The data 
obtained were analyzed statistically with the 
Kolmogorov Smirnov Test to determine the 
normal distribution. Data were analyzed by 
one-way ANOVA followed Post Hoc Test and 
Tuckey test to compare the percentage decrease 
or increase in blood hematology profile and the 
number of lymphocytes CD4+ and CD8+ inter-
group study with 95% confidence level. 
RESULTS AND DISCUSSION 
 
The Content of 1,8-cineol in ECD Using 
Gas Chromatography 
Distillate obtained from 300 grams of 
dried cardamom was as much as 13.5 ml. 
Distillate obtained was colorless, clear, and oily 
stored in dark glass bottles and in the 
refrigerator to avoid oxidation process that can 
damage the distillate. Further test using gas 
chromatography (GC) was done as a qualitative 
parameter to determine the compound 1,8-
cineol contained in the ECD. GC test performed 
using cineol as standard compound. 
 
Table I. Retention Time and Concentration of Compound in ECD from Gas Chromatography 
Profile 
No Sample Peak Retention Time 
(min) 
Concentration 
(%) 
Compound Name 
1 ECD 1 1,279 0,206 - 
  2 1,891 0,148 - 
  3 1,958 0,934 - 
  4 2,108 2,855 - 
  5 2,188 0,523 - 
  6 2,515 33,828 Cineol 
  7 2,704 0,154 - 
  8 2,808 6,528 - 
  9 3,623 2,669 - 
  10 3,783 5,783 - 
  11 4,088 1,435 - 
  12 4,390 0,366 - 
  13 4,532 0,071 - 
  14 4,668 1,073 - 
  15 4,930 0,504 - 
  16 5,587 41,715 - 
  17 5,735 0,018 - 
  18 6,323 0,053 - 
  19 7,223 0,071 - 
  20 7,856 0,848 - 
  21 8,041 0,113 - 
  22 11,171 0,104 - 
2 Standardcompound 
(cineol) 
1 1,176 0,0 - 
 2 2,525 0,0 Cineol 
 
Gochev et al., (2012) reported that the 
main content of the cardamom distillate is 1.8-
cineol (21-41 %) and α- terpene acetate (21-35 
%). The compound 1,8-cineol is reported to 
have efficacy to induce apoptosis through 
fragmentation oligonucleoside (Moteki et al., 
2002). This compound is also performs as 
chemoprevention agent chemotherapy 
(Wattenberg and Morse, 1992) and capable to 
stimulate an immune response through 
increased phagocytic ability of macrophages 
(Serafino et al., 2008).  
 
ECD Repair Hematology Profile against 
Immunosupressan Effect of Doxorubicin 
In this study, haematology profile such 
as leukocytes, lymphocytes, neutrophils, and 
platelets were observed in rats treated with 
doxorubicin and ECD (Fig.1). Based on the 
results of the statistical test is known that there 
are significant differences in the number of 
leukocytes, lymphocytes, and platelets each 
treatment group compared with untreated 
group. The results of this study indicate that 
treatment with ECD at 100 mg/Kg BW did not 
decrease the number of cells in hematology 
Raksamiharja, et al., 2012 
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profile, but intended to increase the number of 
leukocytes, lymphocytes, and neutrophils. It is 
seen from the data the percentage of blood 
component number of ECD treated group at 
100 mg/Kg BW which was always positive and 
not significantly different compared with the 
untreated controls. 
 
 
Figure 1. ECD Repair Hematology Profile against Immunosupressan Effect of Doxorubicin. 
Sprague dawley rat was given with doxorubicin and ECD for 11 days and the blood 
sample was taken and analyzed with haematology analyzer as described in the 
methods. The negative sign indicates a decrease. (*) Indicates data was significantly 
different (p <0.05). (**) Indicates the data was not significantly different (p<0.05). 
Whole bloods from each group were analyzing using hematology analyzer. Changes in 
the number of leukocytes, lymphocytes, neutrophils, and platelets were tested using 
one-way ANOVA with 95% confidence level. 
 
Cancer therapy using doxorubicin caused 
side effects including cell resistance, 
cardiotoxicity and decreased immune system. 
The suppression of immune system will lead to 
patient susceptible to infections and other 
diseases (Patel et al., 2007). Previous study 
from Zhang et al. (2005) showed that 
doxorubicin inhibits lymphocyte proliferation 
and decrease the number of leukocytes as the 
result. Doxorubicin can cause DNA damage in 
cells of the spinal cord (Uspenskaya et al., 
2004), leading to suppression of immune cells. 
Doxorubicin is cytotoxic to cells which are 
actively divided. Bone marrow cells that are the 
origin of blood cells are cells that have the 
ability to continue to divide. Therefore, it is 
certain that the reduction in the number of 
leukocytes, lymphocytes, neutrophils, and 
platelets in the doxorubicin group. 
ECD Improve Specific Immune State 
through Increased the Number of CD4+ 
and CD8+ 
There are 3 types of differentiation of 
lymphoid pathway namely B lymphocytes, T 
lymphocytes, and natural killer cells. 
Lymphocytes are the specific immune system 
which has activities in the fight against cancer 
cells. In this study, cardamom distillate 
expected has potency to increase the number of 
leukocytes and lymphocytes.  It is possible that 
the cardamom distillate has action to improve 
the immune system by increasing the specific 
immune system. To know the state of the 
specific immune system, the study was 
conducted determination of the number of 
lymphocytes CD4+ and CD8+. 
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Figure 2. ECD Improve Specific Immune State through Increased the Number of CD+3, CD+4 and 
CD+8. Sprague dawley rat was given with doxorubicin and ECD for 11 days, and the blood 
sample was taken and subjected for flowcytometry analysis as described in the methods. 
The data showed that ECD tend to increase number of CD+3 (a), CD+4 and CD+8 
lymphocyte cells (b). (*) Indicates data was significantly different (p <0.05). (**) Indicates 
the data was not significantly different (p<0.05). 
 
ECD control group at dose 100 mg/Kg 
BW tend to reduce the number of lymphocytes 
CD4+ and CD8+ compare to untreated group. 
Doxorubicin group also experienced a 
significant decrease when compared to the 
untreated control group in the number of 
lymphocytes CD4+ and CD8+. ECD treatment 
dose of 5 mg/Kg BW, 50 mg/Kg BW and 100 
mg/Kg BW combination with doxorubicin 7.5 
mg/kg body weight showed there is no 
improvement of lymphocytes CD4+ and CD8+ 
profile significantly. This shows the  inability 
of ECD at dose 5 mg/Kg BW, 50 mg/Kg BW 
and 100 mg/Kg BW to improve specific 
immune system due to a decrease in the side 
effects of chemotherapy agent doxorubicin. 
Compound 1,8-cineol performs anti-
inflammatory activity through the inhibition 
mechanism of the expression of pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-
α), COX-2, and activation of NF-κB (Cho , 
2013). In cases of acute inflammatory, role of 
TNF-α and other proinflammatory cytokines is 
very beneficial for the body homeostatic. 
However, it’s different with the case of chronic 
inflammatory diseases, for example cancer. 
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Chronic inflammation can occur due to 
persistent antigens in tissues, causing an 
immune response of the body that continuously 
triggers the secretion of pro-inflammatory 
cytokines. According to Aggarwal et al. (2006), 
it can even be linked to all stages of the process 
of carcinogenesis, including cellular 
transformation, proliferation, invasion, 
angiogenesis, and metastasis. Therefore it can 
be expected role of the compound 1,8-cineol in 
cardamom distillate as an anti -inflammatory 
activity can suppress the activity of TNF-α as 
an endogenous tumor promoter to suppress the 
development of cancer cells. 
Majdalawieh and Carr (2010) states that 
cardamom distillate can increase the cytotoxic 
activity of natural killer cells. Natural killer cell 
has cytotoxic role as the first defense of 
immune system. Natural killer cells and 
lymphocytes formation through lymphoid 
pathway, but natural killer cells doesn’t have 
specific receptors to recognize the target. 
Natural killer cells are very effective in 
attacking the target cells because it can change 
quickly without going through the process of 
genetic structuring like B cells and T cells 
(Jakobisiak et al., 2003). Highactivity of natural 
killer cell could be one of the parameters of the 
ability of anti-cancer agents through increased 
immune system. In the study Hassan et al 
(2010) reported that the α-terpineol, which is 
one component of the cardamom distillate have 
activity as potential anti-cancer agents by 
inhibiting NF-κB pathway. These indicate 
cardamom distillate also has the potential to be 
used as an anti-cancer agent than as 
immunostimulant agents. 
Treatment with ECD improve the state 
of the immune cells through the increase in the 
number of leukocytes, lymphocytes, and 
neutrophils, but have not been able to repair a 
decrease in the number of lymphocytes CD4+ 
and CD8+ in female Sprague Dawley rats after 
doxorubicin chemotherapy. Further research is 
needed to investigate activity of ECD in other 
immune mechanism.  
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